Investors applauded the company's latest clinical results.
News & Analysis: GENFIT SPON ADS EACH REP 1 ORD SHS
One of the company's pipeline candidates flopped in a late-stage clinical trial.
Both companies aim to grab a piece of the multi-billion dollar market for treating patients with the liver disease NASH. So, which one should you buy?
An investment bank analyst thinks this biotech stock is worth more than twice its recent price.
They're risky, but these up-and-coming biotechs could be tremendous winners for investors willing to take on those risks.
Genfit, Changyou, and Children's Place aren't turning heads on Wall Street quite yet, but that could change very soon.